Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00215436
NCT00215436
Completed
Phase 3

A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Dey1 site in 1 country345 target enrollmentMarch 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOPD
DrugsFormoterol Fumarate

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COPD
Sponsor
Dey
Enrollment
345
Locations
1
Primary Endpoint
Measure of lung function
Status
Completed
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

Registry
clinicaltrials.gov
Start Date
March 2005
End Date
September 2006
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Dey

Eligibility Criteria

Inclusion Criteria

  • •Medical diagnosis of COPD
  • •Current or prior history of cigarette smoking

Exclusion Criteria

  • •Medical diagnosis of asthma
  • •Chest X-ray diagnostic of significant disease other than COPD
  • •Significant condition or disease other than COPD

Outcomes

Primary Outcomes

Measure of lung function

Secondary Outcomes

  • Change in lung function, as well as vital signs
  • Physical Exam results, Adverse event reporting, etc

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPDCOPD
NCT00280371Dey345
Completed
Phase 2
Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe PsoriasisPsoriasis
NCT00333411Boehringer Ingelheim360
Completed
Phase 2
A Study of Enzalutamide and LY3023414 in Men With Prostate CancerProstate Cancer Metastatic
NCT02407054Eli Lilly and Company142
Completed
Phase 2
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque PsoriasisPlaque Psoriasis
NCT01483924ApoPharma60
Completed
Phase 2
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureSedationAnxietyPain
NCT00894699Talphera, Inc40